Today marks a major milestone for our company and the OSA community—our landmark Phase 3 SynAIRgy trial met its primary endpoint. Learn more:

While preparing sleep-related teaching materials as a research assistant, Miranda realized that she had been experiencing OSA symptoms for much of her life. Read her OSA story and how this diagnosis has ignited a personal passion for neuroscience:

😴 OSA isn’t just about bad sleep—it’s a serious health risk. When left untreated, it can lead to long-term, potentially life-threatening complications. Hear what Dr. Nate Watson says your next step should be if you’re having trouble sleeping.

You'd expect to struggle to catch your breath summiting Mt. Everest—not every night while you sleep. OSA reduces blood oxygen levels that can cause blood pressure spikes and heart rate fluctuations. Learn more about the burden of decreased oxygen in OSA:

Men and women experience OSA differently, and we’ve got the data to prove it. At 10AM, join Monica Mallampalli in Exhibit Hall 4E as she dives into the gender-specific psychosocial burden of OSA, backed by insights from our SHINE survey, at #SLEEP2025.

Congratulations to Dr. Nate Watson for being honored with @AASMorg’s 2025 Sleep Health Advocate Award. Hear why he’s so passionate about sleep health and his words of encouragement for his colleagues.

While treatment options exist for OSA, many people living with it struggle to tolerate the standard treatment. 📣 Today at 10 AM during #SLEEP2025, join us in Exhibit Hall 4E as Dr. Nate Watson spotlights the critical gaps in diagnosis and treatment of OSA:

Revealing data presented at #SLEEP2025 estimates >80 million Americans have OSA and many are unaware, which can lead to serious health consequences. Join us at 10AM in Exhibit Hall 4E as we shine a light on this burden—and hear how we’re changing the story:

Right on the heels of announcing our first Phase 3 topline results, we’re gearing up to highlight the disease burden and unmet medical needs in OSA at #SLEEP2025. Make sure our presentations are part of your conference plan:

Failure to effectively treat OSA can have a lasting impact on overall health and quality of life. Up to 80% of people living with OSA are undiagnosed. Learn how we’re working to simplify solutions for people with OSA:

Join us at #ATS2025 to explore the demographics and baseline disease characteristics of our Phase 3 LunAIRo study, evaluating investigational AD109 in people with OSA. The study includes a diverse group of people with mild, moderate, or severe OSA:

We’re on a mission to transform the treatment of OSA. Stop by our booth at #ATS2025 for a quick chat, a fresh perspective on OSA, and a peek into what’s ahead for sleep medicine. Let’s talk science, innovation—and better sleep for millions.

"Sleep apnea can actually affect anyone of any age, of any sex and body type. There really isn't any single face of the disease.". @ParadeMagazine talked to Miranda Chappel-Farley about the close call that ultimately led to her OSA diagnosis.

We can’t wait to see you at #ATS2025! Stop by our booth to learn more about our efforts to develop an oral therapy to treat obstructive sleep apnea and make sure our presentation on the patient demographics of our Phase 3 LunAIRo trial is on your calendar.

OSA can have a profound impact on everyday life. The SHINE survey, sharing the psychological burden experienced by those with OSA, unpacks these often-overlooked aspects of OSA. Learn more: #MentalHealthAwarenessMonth

A study of more than 12,000 adults found that nearly half of people with OSA are not obese. While obesity is a primary risk factor for this sleep-related breathing disease, many other factors often play a role. Read more in @NewsMedical:

Last week, our team celebrated #SleepApneaEducationWeek, joining forces with @OfApnea and @project_sleep to break stereotypes and spread information about OSA. Let’s face sleep apnea together and make it a national priority year-round!

We’re excited to have acquired the intellectual property and exclusive global rights to develop and commercialize sulthiame, a differentiated carbonic anhydrase inhibitor, in the field of sleep-related breathing diseases. Review our expanding portfolio:

Let’s face OSA together! Our team is rallying behind @project_sleep and its work to shatter stereotypes and showcase the real faces of those living with OSA. Learn more about the “Let’s Face It” campaign.

We stand with @OfApnea this #SleepApneaEducationWeek to make sleep apnea a national priority, doing our part to raise awareness and prioritize new treatment options to positively impact those living with OSA. Together, we can pioneer solutions. Learn more: